Literature DB >> 35121842

A bright future for KRAS inhibitors.

Dafna Bar-Sagi1, Erik H Knelson2,3,4, Lecia V Sequist5,6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 35121842     DOI: 10.1038/s43018-019-0016-8

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


× No keyword cloud information.
  8 in total

1.  Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells.

Authors:  Jang Hee Han; Yong Keon Kim; Hakhyun Kim; Jooyoung Lee; Myung Joon Oh; Sang Bum Kim; Minjee Kim; Kook Hwan Kim; Hyun Ju Yoon; Myung-Shik Lee; John D Minna; Michael A White; Hyun Seok Kim
Journal:  Cancer Commun (Lond)       Date:  2022-07-15

Review 2.  The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.

Authors:  Alessia Spagnuolo; Paolo Maione; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2022-06

3.  Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.

Authors:  Jaewon Choi; Scott P Goulding; Brandon P Conn; Christopher D McGann; Jared L Dietze; Jessica Kohler; Divya Lenkala; Antoine Boudot; Daniel A Rothenberg; Paul J Turcott; John R Srouji; Kendra C Foley; Michael S Rooney; Marit M van Buuren; Richard B Gaynor; Jennifer G Abelin; Terri A Addona; Vikram R Juneja
Journal:  Cell Rep Methods       Date:  2021-09-16

Review 4.  Toward personalized treatment approaches for non-small-cell lung cancer.

Authors:  Meina Wang; Roy S Herbst; Chris Boshoff
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

Review 5.  Precision medicine for metastatic colorectal cancer in clinical practice.

Authors:  Julian E Riedesser; Matthias P Ebert; Johannes Betge
Journal:  Ther Adv Med Oncol       Date:  2022-01-19       Impact factor: 8.168

6.  Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds.

Authors:  Chiara Pallara; Debora Cabot; Josep Rivas; Sonia Brun; Jesús Seco; Baraa Abuasaker; Teresa Tarragó; Montserrat Jaumot; Roger Prades; Neus Agell
Journal:  Sci Rep       Date:  2022-09-22       Impact factor: 4.996

Review 7.  Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.

Authors:  Elona Cekani; Samantha Epistolio; Giulia Dazio; Marco Cefalì; Luciano Wannesson; Milo Frattini; Patrizia Froesch
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

Review 8.  The Research Progress of Direct KRAS G12C Mutation Inhibitors.

Authors:  Ai Yang; Min Li; Mingzhi Fang
Journal:  Pathol Oncol Res       Date:  2021-04-23       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.